These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 28514998)

  • 1. Affibody Molecules in Biotechnological and Medical Applications.
    Ståhl S; Gräslund T; Eriksson Karlström A; Frejd FY; Nygren PÅ; Löfblom J
    Trends Biotechnol; 2017 Aug; 35(8):691-712. PubMed ID: 28514998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications.
    Löfblom J; Feldwisch J; Tolmachev V; Carlsson J; Ståhl S; Frejd FY
    FEBS Lett; 2010 Jun; 584(12):2670-80. PubMed ID: 20388508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bacterial Cell Display for Selection of Affibody Molecules.
    Dahlsson Leitao C; Ståhl S; Löfblom J
    Methods Mol Biol; 2023; 2681():99-112. PubMed ID: 37405645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Update: affibody molecules for molecular imaging and therapy for cancer.
    Orlova A; Feldwisch J; Abrahmsén L; Tolmachev V
    Cancer Biother Radiopharm; 2007 Oct; 22(5):573-84. PubMed ID: 17979560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Engineered affinity proteins for tumour-targeting applications.
    Friedman M; Ståhl S
    Biotechnol Appl Biochem; 2009 May; 53(Pt 1):1-29. PubMed ID: 19341363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Affibody molecules as engineered protein drugs.
    Frejd FY; Kim KT
    Exp Mol Med; 2017 Mar; 49(3):e306. PubMed ID: 28336959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Site-specific radiometal labeling and improved biodistribution using ABY-027, a novel HER2-targeting affibody molecule-albumin-binding domain fusion protein.
    Orlova A; Jonsson A; Rosik D; Lundqvist H; Lindborg M; Abrahmsen L; Ekblad C; Frejd FY; Tolmachev V
    J Nucl Med; 2013 Jun; 54(6):961-8. PubMed ID: 23528382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel affinity binders for neutralization of vascular endothelial growth factor (VEGF) signaling.
    Fleetwood F; Güler R; Gordon E; Ståhl S; Claesson-Welsh L; Löfblom J
    Cell Mol Life Sci; 2016 Apr; 73(8):1671-83. PubMed ID: 26552422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inflammation and neurodegenerative disorders: is there still hope for therapeutic intervention?
    Baune BT
    Curr Opin Psychiatry; 2015 Mar; 28(2):148-54. PubMed ID: 25602246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Engineering of Affibody Molecules.
    Ståhl S; Lindberg H; Hjelm LC; Löfblom J; Dahlsson Leitao C
    Cold Spring Harb Protoc; 2023 Jul; ():. PubMed ID: 37491082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular Mechanisms and Therapeutic Effects of (-)-Epicatechin and Other Polyphenols in Cancer, Inflammation, Diabetes, and Neurodegeneration.
    Shay J; Elbaz HA; Lee I; Zielske SP; Malek MH; Hüttemann M
    Oxid Med Cell Longev; 2015; 2015():181260. PubMed ID: 26180580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular design and optimization of 99mTc-labeled recombinant affibody molecules improves their biodistribution and imaging properties.
    Wållberg H; Orlova A; Altai M; Hosseinimehr SJ; Widström C; Malmberg J; Ståhl S; Tolmachev V
    J Nucl Med; 2011 Mar; 52(3):461-9. PubMed ID: 21321280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design of an optimized scaffold for affibody molecules.
    Feldwisch J; Tolmachev V; Lendel C; Herne N; Sjöberg A; Larsson B; Rosik D; Lindqvist E; Fant G; Höidén-Guthenberg I; Galli J; Jonasson P; Abrahmsén L
    J Mol Biol; 2010 Apr; 398(2):232-47. PubMed ID: 20226194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alternative binding proteins: affibody binding proteins developed from a small three-helix bundle scaffold.
    Nygren PA
    FEBS J; 2008 Jun; 275(11):2668-76. PubMed ID: 18435759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generation of tumour-necrosis-factor-alpha-specific affibody molecules capable of blocking receptor binding in vitro.
    Jonsson A; Wållberg H; Herne N; Ståhl S; Frejd FY
    Biotechnol Appl Biochem; 2009 Aug; 54(2):93-103. PubMed ID: 19545237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generation of affibody molecules specific for HPV16 E7 recognition.
    Xue X; Wang B; Du W; Zhang C; Song Y; Cai Y; Cen D; Wang L; Xiong Y; Jiang P; Zhu S; Zhao KN; Zhang L
    Oncotarget; 2016 Nov; 7(45):73995-74005. PubMed ID: 27659535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of four affibody-based near-infrared fluorescent probes for optical imaging of epidermal growth factor receptor positive tumors.
    Qi S; Miao Z; Liu H; Xu Y; Feng Y; Cheng Z
    Bioconjug Chem; 2012 Jun; 23(6):1149-56. PubMed ID: 22621238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of DOTA chelator position on biodistribution and targeting properties of (111)In-labeled synthetic anti-HER2 affibody molecules.
    Perols A; Honarvar H; Strand J; Selvaraju R; Orlova A; Karlström AE; Tolmachev V
    Bioconjug Chem; 2012 Aug; 23(8):1661-70. PubMed ID: 22768790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of backbone-cyclized HER2-binding 2-helix affibody molecule for in vivo molecular imaging.
    Honarvar H; Jokilaakso N; Andersson K; Malmberg J; Rosik D; Orlova A; Karlström AE; Tolmachev V; Järver P
    Nucl Med Biol; 2013 Apr; 40(3):378-86. PubMed ID: 23357083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Engineered high-affinity affibody molecules targeting platelet-derived growth factor receptor β in vivo.
    Lindborg M; Cortez E; Höidén-Guthenberg I; Gunneriusson E; von Hage E; Syud F; Morrison M; Abrahmsén L; Herne N; Pietras K; Frejd FY
    J Mol Biol; 2011 Mar; 407(2):298-315. PubMed ID: 21277312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.